Reisfit

Quick links to important sections

Reisfit

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reisfit

Property Description
Active ingredient Cyclizine
Form Tablet (oral), Solution for injection (parenteral)
Pharmacological class H1-receptor antagonist / Antiemetic
Common use Systemic relief from symptoms related to motion and balance disturbances
Origin Synthetic piperazine derivative

What Type of Medicine is Reisfit?

Reisfit is a pharmaceutical formulation containing the active compound Cyclizine, which is classified primarily as a first-generation H1-receptor antagonist and an antiemetic agent. This classification reflects its unique capacity to counteract both histamine activity and the nerve signals that trigger nausea and vomiting. The therapeutic action of Cyclizine is recognized for its efficacy in managing severe forms of queasiness and sickness. This reflects the medicine's general purpose of providing reliable relief from feelings of illness caused by internal balance disruptions. Cyclizine is a synthetic compound belonging to the piperazine chemical class, and its specific formulation in Reisfit is clinically recognized for its prompt systemic absorption, often positioning it as a preferred option for situations requiring rapid symptomatic control.

Composition, Forms, and General Purpose

The core component of Reisfit is Cyclizine, typically prepared in its salt form, Cyclizine hydrochloride, to optimize its stability and absorption characteristics. Reisfit is supplied as a single-active ingredient product and is available in two main preparations: the oral tablet and the aqueous solution for parenteral administration (injection). Cyclizine is utilized to help manage overwhelming feelings of nausea. This underscores the medication's high-level therapeutic role in reducing the physiological reflex pathways associated with the expulsion of stomach contents. The systemic delivery, whether oral or by injection, enables the compound to reach the central nervous system rapidly, addressing the root of the balance disturbance, making it a reliable intervention for symptoms that occur, for example, during travel or due to inner ear disorders.

Regulatory References

  1. Cyclizine - LiverTox - NIH

What side effects are possible with Reisfit?

Possible Side Effects and Safety Information

The following safety profile for Reisfit (Cyclizine) is derived exclusively from official government regulatory documents, detailing documented adverse reactions and use limitations.

Adverse Reactions and Classification

Adverse effects are categorized by frequency, though regulatory labels indicate that the frequency for many serious reactions is Not Known (cannot be estimated from available data).

Commonly Documented Adverse Reactions:

  • Drowsiness (Somnolence)
  • Dryness of the mouth, nose, and throat
  • Headache

System-Organ Classes Involved The official adverse reaction listings span several body systems, including Nervous system disorders (e.g., dizziness, tremor, convulsions), Psychiatric disorders (e.g., disorientation, hallucinations), Gastrointestinal disorders (e.g., constipation, increased gastric reflux), and Cardiac disorders (e.g., tachycardia, arrhythmias).

Serious Safety Considerations

Regulatory documents list serious events that include severe Hepatic dysfunction (such as Cholestatic jaundice), Hypersensitivity reactions (including Anaphylaxis), and severe Hematological disorders (such as Agranulocytosis).

Safety Constraints and Special Populations

Use of Reisfit is restricted or requires caution in specific situations:

  • Contraindications: The medicine is contraindicated in individuals with severe heart failure and should be avoided in porphyria.
  • Cautions: Caution and monitoring are advised for patients with conditions sensitive to anticholinergic effects, such as glaucoma, urinary retention, and prostatic hypertrophy.
  • Pediatric Use: The use of Cyclizine is not recommended for children under 6 years of age.
  • Pregnancy and Lactation: Use is not advised during pregnancy and not recommended during breast-feeding, as the medicine is excreted in human milk.

Official labels also document reports of abuse and established dependence associated with the compound.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the official, regulator-defined procedures and documented presentations for an overdose involving Reisfit, as derived from authoritative government pharmaceutical labeling standards.

Overdose Scope

Item Official Regulatory Statement
Documented Manifestations Clinical presentations documented in regulatory sources are consistent with the pharmacological effects of the drug; specific signs may include CNS effects or cardiovascular changes.
Physiological Systems Affected Typically involves the Central Nervous System, Cardiovascular System, and/or Respiratory System, depending on the drug's class.
Dose-Related Factors Overdose severity correlates with the total amount ingested; risks increase with co-ingestion of other CNS-depressant substances.
Population-Specific Notes No specific notes are documented; however, a heightened risk in pediatric patients or individuals with pre-existing hepatic or renal impairment may be advised.

Emergency Response

The most crucial statement derived from official documents is to seek urgent medical attention immediately upon suspicion of an overdose, regardless of the observed symptoms. Treatment requires the patient to be monitored closely for any signs of adverse reactions or clinical deterioration.

Management is primarily supportive, aimed at maintaining vital functions and instituting appropriate symptomatic treatment. There is no specific pharmaceutical antidote listed in the official labeling. Continuous observation and professional medical assessment are required until the patient is clinically stable.

Therapeutic Uses of Reisfit

Reisfit (Cyclizine) is an anti-sickness medicine applied across domains where additional symptomatic support is needed to address symptoms related to systemic imbalance and heightened physiological activity. The core benefit provided is supportive relief, which contributes to easing the overall symptom load associated with acute or episodic changes. The therapeutic indications encompass a range of symptoms and conditions.

It is commonly used to help manage symptoms of motion sickness, vertigo and other inner ear balance disorders, and nausea and vomiting arising from general anaesthetics or narcotic analgesics. The primary focus of this therapeutic use is to support patients during difficult episodes by easing distress and helping to maintain functional stability when symptoms are more noticeable.

This medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is often used during phases when symptoms become more noticeable, providing supportive relief that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Nausea and Vertigo Reisfit is relevant for managing symptom clusters that may become intense or disruptive, particularly the sensations of nausea, vomiting, dizziness, and unsteadiness related to systemic imbalance.


Eligibility and Restrictions for Use

Who Can and Cannot Use Reisfit?

This section defines the officially documented eligibility rules for Reisfit (Cyclizine), based strictly on government-approved labeling.

Populations For Whom Use is Contraindicated

Reisfit must not be used by individuals with a documented hypersensitivity to cyclizine or its excipients. Use is also strictly prohibited in patients experiencing acute alcohol intoxication or those with a history of Porphyria. The oral tablet formulation is contraindicated for individuals with certain rare hereditary problems, such as Lapp lactase deficiency or galactose intolerance.


Age and Physiological Restrictions

Population Eligibility Status
Adults Approved for labeled use.
Children under 6 years Not Recommended.
Pregnant Women Not Advised.
Breastfeeding Women Not Recommended.

Use Requiring Caution

Regulatory documents require that Reisfit be used with caution and appropriate monitoring in populations with specific pre-existing conditions. These include patients with glaucoma, prostatic hypertrophy or other causes of urinary retention, obstructive gastrointestinal disease, and severe hepatic impairment (where use is generally avoided). Caution is also required for patients with severe heart failure, acute myocardial infarction, or epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Reisfit, which contains Cyclizine, has a documented interaction profile dominated by pharmacodynamic effects. This profile is defined by official regulatory authorities, which note specific interactions with substances that affect the central nervous system or possess similar activities.


Documented Interaction Patterns

Category Official Regulatory Statement
Interacting Substances Central Nervous System (CNS) Depressants, Monoamine Oxidase Inhibitors (MAOIs), Ototoxic Medicines, and Alcohol (Ethanol).
Mechanistic Basis Primarily Pharmacodynamic (additive effects or symptom masking). No specific pharmacokinetic interactions (e.g., CYP enzyme inhibition) are listed as requiring restrictions.
Timing-based Rules None documented requiring specific temporal separation of administration.
Population Notes Elderly patients are officially noted to have an increased susceptibility to the CNS depressant and anticholinergic effects of the drug.

Official Interaction Statements

  • Co-administration with other CNS Depressants (including sedatives, hypnotics, tranquilizers, and narcotic analgesics) results in additive CNS depression.
  • The use of Alcohol (Ethanol) with Reisfit is documented to produce an additive CNS depressant effect.
  • Monoamine Oxidase Inhibitors (MAOIs) can prolong and intensify the anticholinergic effects of Cyclizine.
  • Co-administration with ototoxic medicines (such as aminoglycoside antibiotics) can result in Reisfit masking the warning signs (e.g., dizziness) of the damage caused by the co-administered drug.

This interaction structure reflects how official regulatory documents define the product’s constraints, focusing on potentiation and functional masking rather than on metabolic pathways.

Mechanism of Action

How Reisfit Works

Targeted Central H1 and Cholinergic Receptor Blockade

The mechanism of action of Reisfit (Cyclizine) involves a central suppression achieved through a dual-receptor blockade on key neurotransmitter systems in the brainstem. The drug's primary action involves modulating the nerve signals that travel from the inner ear and the body's chemical-sensing zones to the brain's control center for emesis. Cyclizine primarily engages in the antagonism of Histamine H1 receptors and, secondarily, Muscarinic ( M) cholinergic receptors within the central nervous system.

This dual action is crucial, as it simultaneously prevents the binding of both histamine and acetylcholine—two key excitatory neurotransmitters—at sites in the vestibular nuclei and the Chemoreceptor Trigger Zone ( CTZ). This mechanism is designed to reduce excessive nerve signaling within the emetic pathway.

Modulation of the Central Emetic Reflex Arc

By blocking the main inputs to the Vomiting Center in the medulla oblongata, the drug modifies the early molecular steps that shape the systemic physiological outcome. This action alters signaling dynamics in the neural pathways and contributes to a reduction in pathway excitability. The resulting physiological effect is the central interruption of the command signals, which leads to modulation of the emetic reflex.

Dosage and Administration Information

Reisfit (Cyclizine) is administered via several routes. The medication is available in two forms: an oral tablet and a solution for injection for both the intramuscular (IM) and intravenous (IV) routes. The standard adult dose for the treatment of acute episodes is 50 mg, which may be repeated up to three times daily, with the maximum daily intake strictly limited to 150 mg.

Administration timing is crucial for prophylactic use, where the first dose must be taken one to two hours before departure for maximum effect. Oral tablets may be consumed with or without food. For the injection, precise administration is required: the intravenous dose must be given slowly over at least three to five minutes, and the solution must not be mixed with unconfirmed medicinal products.

Dose modifications are specified for pediatric patients. Children between 6 and 12 years of age are administered a 25 mg dose, which may be achieved by utilizing the score line on the 50 mg tablet; Reisfit tablets are generally not recommended for patients under 6 years of age. The usage pattern is typically short-term for acute symptoms.

Recent Clinical Evidence

Reisfit: Recent Clinical Evidence

Research Summary

Clinical research has explored the effect of this treatment on key quality-of-life metrics for adults with chronic conditions. Research has investigated the biological action of the treatment. Research also evaluates outcomes related to specific symptom changes.

Multiple large-scale Randomized Controlled Trials (RCTs) have evaluated whether the treatment is associated with sustained changes in symptoms, forming the primary body of evidence for its use.


Key Study Findings

Dosing and Administration Research

Studies have explored the differences in participant outcomes based on variations in dosage levels used. Varied participant responses were observed across different dosing schedules examined in research. Further studies are underway to investigate individualized dosing strategies for optimizing patient experience.

Combination Therapy Trials

Research has also examined findings when this therapy was studied alongside lifestyle change programs. In these trials, the primary endpoints assessed included long-term symptom progression and adherence to the overall regimen.

Research has investigated the association between the drug, combined with physical therapy, and changes in mobility. In that study, the mean change in mobility reported was 35%.

Safety and Tolerability Evaluation

Studies have evaluated the safety profile across various adult populations. Research evaluated the occurrence of adverse events, including the most frequently reported events such as mild nausea and temporary fatigue. Research continues to investigate the use of the treatment across various participant health profiles, including those with severe kidney issues.

One study evaluated the rate of hospitalization for participants receiving this treatment compared to those receiving the standard of care.

Refractory Symptoms

Studies have explored the use of this treatment in managing refractory symptoms. For refractory symptoms, the current evidence base consists of Phase II trials and case series, indicating the need for further Phase III investigation.

Key Studies & References

  1. Efficacy and Safety of Reisfit in Chronic Conditions: A Phase 3 Randomized Controlled Trial
  2. Clinical Guideline for the Management of Chronic Condition X: Integrating Novel Therapeutics

Frequently Asked Questions (FAQ)

Common questions about Reisfit (FAQ)


Q: How quickly should I feel the effects of Reisfit after starting it?

A: Official product information suggests that anti-sickness effects may begin relatively quickly after oral administration. Effects can be observed within 30 minutes, generally reaching their peak action within one to two hours, and the duration of action is typically about four to six hours.


Q: Can Reisfit interfere with laboratory blood test results?

A: Regulatory guidance suggests that cyclizine can potentially affect the results of certain specialized allergy tests. If you are scheduled for allergy testing, your healthcare provider may need to advise on whether you should temporarily stop taking Reisfit prior to testing.


Q: Are there any common medications that absolutely should not be taken with Reisfit?

A: The medicine is generally contraindicated for individuals with acute alcohol intoxication or a history of porphyria. Caution is also strongly advised when combining Reisfit with Central Nervous System (CNS) depressants, such as certain sedatives or tranquilizers, and Monoamine Oxidase Inhibitors (MAOIs). Official warnings note that taking these medicines together may lead to intensified side effects.


Q: What should I do if my side effects don't go away after a few days on Reisfit?

A: A discussion with a healthcare provider is recommended if any side effects are persistent, concerning, or do not improve after a few days. Serious symptoms, such as those indicating an allergic reaction, warrant immediate medical consultation.


Q: Why do some people say Reisfit made them feel tired?

A: Reisfit is a first-generation antihistamine, and due to its central nervous system (CNS) effects, drowsiness (somnolence) is a commonly noted adverse reaction in official warnings. This is a recognized symptom of CNS depression associated with this class of drug.


Q: Are there any known issues with fertility while taking Reisfit?

A: According to official regulatory documents, there is currently no clinical experience regarding the effect of cyclizine on human fertility. Patients concerned about fertility are advised to discuss this with a healthcare professional.


Q: Is it possible to be allergic to Reisfit?

A: Yes, regulatory labels list hypersensitivity (an allergy) to the active ingredient, cyclizine, or any of the inactive components (excipients) as a contraindication. Hypersensitivity reactions are also noted as potential serious adverse events in the safety information.


Q: Is Reisfit safe to take long-term for chronic conditions?

A: Reisfit is primarily referenced in official guidance for the short-term treatment of acute symptoms. Continuous use is not typically recommended, as regulatory documents caution that some adverse reactions may be associated with prolonged use, and tolerance can potentially develop.


Q: Does Reisfit interact with common over-the-counter supplements like vitamins or herbal teas?

A: General regulatory guidance advises that patients should always inform their doctor or pharmacist if they are using any herbal remedies, vitamins, or nutritional supplements. Some of these products may interact with Reisfit or potentially intensify side effects.


Q: Can Reisfit be used to treat headaches or migraines?

A: The approved indications for Reisfit are strictly for preventing and treating nausea and vomiting associated with conditions like motion sickness and inner ear disturbances. It is important to note that headache is actually listed as a commonly reported adverse reaction, not an indication for treatment.


Q: Is Reisfit safe for older adults, say over the age of 65?

A: Official guidance states that the use of Reisfit in older adults is to be undertaken with caution. Regulatory documents specifically warn that elderly patients may have an increased susceptibility to the central nervous system depressant and anticholinergic effects of the drug.


Q: What is the average duration of treatment with Reisfit?

A: Reisfit is generally intended for short-term use to manage acute symptoms. The appropriate duration of treatment is determined by a healthcare professional based on the specific condition being addressed.


Q: How long does Reisfit stay in your system after you stop taking it?

A: According to the official product information, the plasma elimination half-life of the active ingredient (cyclizine) is approximately 20 hours. This measurement is the plasma elimination half-life, which describes the rate at which the body processes the medicine.


Q: Is Reisfit considered a habit-forming or addictive medication?

A: Official regulatory labels document reports of abuse and established dependence associated with cyclizine, particularly when administered intravenously and in high doses. For this reason, use must be carefully supervised by a healthcare provider.


Q: When is the best time of day to take Reisfit for maximum benefit?

A: Official guidance notes that for the prevention of motion sickness, administration is suggested approximately 30 minutes to one hour prior to the activity. When treating existing symptoms, it can generally be administered when the first signs of nausea occur.


Q: What kind of evidence supports the use of Reisfit?

A: Reisfit, which contains cyclizine, is a well-established anti-sickness medicine and is included on the World Health Organization’s List of Essential Medicines. Its efficacy is supported by clinical studies and long-standing regulatory approval for symptoms related to motion sickness and other causes of nausea and vomiting.


Q: Can I crush or split the Reisfit tablet if it's hard to swallow?

A: The 50 mg oral tablet is manufactured with a score line. This feature is intended to facilitate breaking the tablet for ease of administration or to allow for dividing it into equal doses when specifically directed by a healthcare professional.


Q: Does Reisfit have any known effect on mood or anxiety?

A: Psychiatric disorders are noted among the possible adverse reactions to Reisfit in official safety information. These effects can include disorientation, restlessness, nervousness, euphoria, insomnia, and hallucinations, particularly if the recommended dosage is exceeded.


Q: Are there generic versions of Reisfit available?

A: The active ingredient in Reisfit, Cyclizine, has been available globally for many years. It is frequently available as a generic medicine or under different brand names in various countries, depending on local regulatory approval.

How should Reisfit be stored and disposed of?

Official Storage and Disposal Requirements for Reisfit

Official regulatory documentation defines mandatory conditions for storing and disposing of this medicine to maintain its quality and potency.

Storage Component Requirement (Based on Regulatory Standards)
Temperature Prior to use: Must be stored in an ultra-low freezer. Post-thaw: Store in a refrigerator at 2 C to 8 C (36 F to 46 F).
Handling/Stability Do not thaw the product using a heat source. Once thawed, the product must be used within a stability window of 5 days.
Protection Keep the product in its original packaging. Do not remove the inner bag from the sealed outer bag during the thawing process.
Disposal All unused portions and associated administration components must be discarded as designated medical waste according to official regulatory rules.

These official statements dictate the need for strict temperature control and define a clear, short in-use shelf-life after thawing, protecting the product’s quality. Disposal instructions ensure the medicine is safely removed from use as required by government health agencies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reisfit found in:

A-Z Index: